BioSpace News Archive

The company’s demise was explained in a blog post by Atlas Venture partner Bruce Booth.

A look at six bay area-based VCs who are creating a lot of value in biotech.

A filing with the SEC indicates that Glaxo now has a 13 percent stake in Spero Therapeutics.

Call to feature key neuro-oncology thought leaders.

Azar, the new HHS nominee, is being pitched as someone who will help lower the price of prescription drugs.

Bloomberg noted that Takeda’s CEO is looking at making Takeda a nimble company, but one with a deeply entrenched R&D focus.

Todd Campbell, writing for The Motley Fool, looks at one of Celgene’s collaborations with a smaller company.

CAR-T is a hot new area and there are companies hot on Gilead’s tail, namely Juno, in a partnership with Celgene, and Novartis.

Hidden gems are long-term market beaters that have market caps below $10 billion and brand names most people won’t recognize.

In collaboration with its partners, the Stem Cell Center aims to accelerate the preclinical/clinical development, and commercialization of stem cell, cellular and gene-modified therapies via end-to-end solutions and targeted services to advance assets from candidate identification through market authorization and improve the probability of clinical and commercial success.